source
- A migraine drugmaker heads to the public markets through reverse mergerMentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can treat migraines that aren’t well controlled by existing drugs.BioPharma Dive · 2mo ago↗ source
- STAT+: Dexcom CEO hints at future uses for CGMIn this edition of STAT Health Tech: Takeaways from a conversation with Dexcom CEO, and updates on WiSeR, and Epic's market share.STAT · 2mo ago↗ source
- STAT+: A new ranking of pharma companies by R&D performanceMaryland drug board to cap price of Ozempic, TrumpRx partners with Cuban, GoodRx, and more biotech newsSTAT · 2mo ago↗ source